Afternoon Market Losers
Synta Pharmaceuticals (NASDAQ: SNTA) is down 32.32% to $4.99 after Synta reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of Ganetespib in second-line non-small cell lung cancer.
Infinity Pharmaceuticals (NASDAQ: INFI) dropped 26.10% to 19.92 on Phase 1 data.
Affymax (NASDAQ: AFFY) dropped 19.23% to $1.68 after this morning's delisting.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.